RedHill Biopharma just swapped the product that defined its commercial identity for a larger, fully controlled gastrointestinal book. In late August the company sold its remaining Talicia interest to Apotex for cash plus contingent sales milestones, and one day later it used most of that cash to license Ferring's Rebyota and Clenpiq. The sequence converts a jointly owned H. pylori franchise into exclusive rights on two already-approved specialty products. Ferring booked about $38 million of United States net sales on that pair in the prior year.
The tension is whether a Tel Aviv and Raleigh microcap with a going concern warning and a Nasdaq bid-price clock can actually operate that larger book. Ferring generated the prior-year sales with its own infrastructure. RedHill brings a lean commercial team that spent the last year sharing Talicia economics with Cumberland and then exiting. The Talicia check of $18 million more than covers the $12 million Ferring upfront. Liquidity improves on paper, yet the residual claim still sits under a warrant-heavy capital structure and a listing deadline in early October.
Year-end cash sat near $4 million against a high-single-digit operating burn and leftover Movantik payables. A June placement added $6 million of cash and a large warrant overhang. The investment question is narrow. Do Rebyota and Clenpiq throw off cash in RedHill's hands before the listing clock or the next dilution event forces another reset?